Recent Finacing
Recent Raise
ImmuneOncia, a Yuhan–Sorrento joint venture, develops immuno-oncology checkpoint monoclonal antibodies—including IMC‑001, a fully human anti‑PD‑L1 in Phase I/II—and earlier-stage programs targeting hematologic and solid tumors.